vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Forestar Group Inc. (FOR). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $273.0M, roughly 1.0× Forestar Group Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 5.6%, a 90.7% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 9.0%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -9.6%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Forestar Group Inc. is a residential lot development company based in Arlington, Texas. The company has operations in 51 markets in 21 states and delivered 11,518 residential lots during the twelve-month period ended December 31, 2020. The company is publicly traded on the New York Stock Exchange and in October 2017 became a majority-owned subsidiary of D.R. Horton, Inc., the largest homebuilder by volume in the United States since 2002. The company primarily acquires entitled real estate and...
ACAD vs FOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $273.0M |
| Net Profit | $273.6M | $15.4M |
| Gross Margin | 90.8% | 20.1% |
| Operating Margin | 6.1% | 7.6% |
| Net Margin | 96.3% | 5.6% |
| Revenue YoY | 9.4% | 9.0% |
| Net Profit YoY | 90.3% | -6.7% |
| EPS (diluted) | $1.61 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $273.0M | ||
| Q3 25 | $278.6M | $670.5M | ||
| Q2 25 | $264.6M | $390.5M | ||
| Q1 25 | $244.3M | $351.0M | ||
| Q4 24 | $259.6M | $250.4M | ||
| Q3 24 | $250.4M | $551.3M | ||
| Q2 24 | $242.0M | $318.4M | ||
| Q1 24 | $205.8M | $333.8M |
| Q4 25 | $273.6M | $15.4M | ||
| Q3 25 | $71.8M | $86.9M | ||
| Q2 25 | $26.7M | $32.9M | ||
| Q1 25 | $19.0M | $31.6M | ||
| Q4 24 | $143.7M | $16.5M | ||
| Q3 24 | $32.8M | $81.5M | ||
| Q2 24 | $33.4M | $38.7M | ||
| Q1 24 | $16.6M | $45.0M |
| Q4 25 | 90.8% | 20.1% | ||
| Q3 25 | 92.2% | 22.3% | ||
| Q2 25 | 92.2% | 20.4% | ||
| Q1 25 | 91.7% | 22.6% | ||
| Q4 24 | 91.6% | 22.0% | ||
| Q3 24 | 92.5% | 23.9% | ||
| Q2 24 | 92.5% | 22.5% | ||
| Q1 24 | 88.8% | 24.9% |
| Q4 25 | 6.1% | 7.6% | ||
| Q3 25 | 12.8% | 16.9% | ||
| Q2 25 | 12.2% | 11.2% | ||
| Q1 25 | 7.9% | 11.6% | ||
| Q4 24 | 59.1% | 8.7% | ||
| Q3 24 | 12.6% | 19.7% | ||
| Q2 24 | 12.6% | 16.2% | ||
| Q1 24 | 7.4% | 17.6% |
| Q4 25 | 96.3% | 5.6% | ||
| Q3 25 | 25.8% | 13.0% | ||
| Q2 25 | 10.1% | 8.4% | ||
| Q1 25 | 7.8% | 9.0% | ||
| Q4 24 | 55.4% | 6.6% | ||
| Q3 24 | 13.1% | 14.8% | ||
| Q2 24 | 13.8% | 12.2% | ||
| Q1 24 | 8.0% | 13.5% |
| Q4 25 | $1.61 | $0.30 | ||
| Q3 25 | $0.42 | $1.70 | ||
| Q2 25 | $0.16 | $0.65 | ||
| Q1 25 | $0.11 | $0.62 | ||
| Q4 24 | $0.86 | $0.32 | ||
| Q3 24 | $0.20 | $1.59 | ||
| Q2 24 | $0.20 | $0.76 | ||
| Q1 24 | $0.10 | $0.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $211.7M |
| Total DebtLower is stronger | — | $793.2M |
| Stockholders' EquityBook value | $1.2B | $1.8B |
| Total Assets | $1.6B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.44× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $211.7M | ||
| Q3 25 | $258.0M | $379.2M | ||
| Q2 25 | $253.6M | $189.2M | ||
| Q1 25 | $217.7M | $174.3M | ||
| Q4 24 | $319.6M | $132.0M | ||
| Q3 24 | $155.1M | $481.2M | ||
| Q2 24 | $177.1M | $359.2M | ||
| Q1 24 | $204.7M | $416.2M |
| Q4 25 | — | $793.2M | ||
| Q3 25 | — | $802.7M | ||
| Q2 25 | — | $872.8M | ||
| Q1 25 | — | $872.5M | ||
| Q4 24 | — | $806.8M | ||
| Q3 24 | — | $706.4M | ||
| Q2 24 | — | $706.1M | ||
| Q1 24 | — | $705.7M |
| Q4 25 | $1.2B | $1.8B | ||
| Q3 25 | $917.3M | $1.8B | ||
| Q2 25 | $822.4M | $1.7B | ||
| Q1 25 | $765.2M | $1.6B | ||
| Q4 24 | $732.8M | $1.6B | ||
| Q3 24 | $577.2M | $1.6B | ||
| Q2 24 | $516.7M | $1.5B | ||
| Q1 24 | $464.0M | $1.5B |
| Q4 25 | $1.6B | $3.2B | ||
| Q3 25 | $1.3B | $3.1B | ||
| Q2 25 | $1.2B | $3.1B | ||
| Q1 25 | $1.1B | $3.0B | ||
| Q4 24 | $1.2B | $3.0B | ||
| Q3 24 | $976.9M | $2.8B | ||
| Q2 24 | $914.1M | $2.7B | ||
| Q1 24 | $855.1M | $2.6B |
| Q4 25 | — | 0.44× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.47× | ||
| Q1 24 | — | 0.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $-157.0M |
| Free Cash FlowOCF − Capex | — | $-157.1M |
| FCF MarginFCF / Revenue | — | -57.5% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | -0.18× | -10.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $93.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $-157.0M | ||
| Q3 25 | $74.3M | $256.3M | ||
| Q2 25 | $64.0M | $15.8M | ||
| Q1 25 | $20.3M | $-19.8M | ||
| Q4 24 | $40.4M | $-450.0M | ||
| Q3 24 | $63.2M | $119.2M | ||
| Q2 24 | $25.0M | $-61.7M | ||
| Q1 24 | $29.1M | $-59.2M |
| Q4 25 | — | $-157.1M | ||
| Q3 25 | $73.9M | $255.6M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $-20.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | $118.4M | ||
| Q2 24 | — | $-62.3M | ||
| Q1 24 | — | $-59.8M |
| Q4 25 | — | -57.5% | ||
| Q3 25 | 26.5% | 38.1% | ||
| Q2 25 | — | 3.8% | ||
| Q1 25 | — | -5.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | 21.5% | ||
| Q2 24 | — | -19.6% | ||
| Q1 24 | — | -17.9% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | 0.1% | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | -0.18× | -10.19× | ||
| Q3 25 | 1.03× | 2.95× | ||
| Q2 25 | 2.40× | 0.48× | ||
| Q1 25 | 1.07× | -0.63× | ||
| Q4 24 | 0.28× | -27.27× | ||
| Q3 24 | 1.93× | 1.46× | ||
| Q2 24 | 0.75× | -1.59× | ||
| Q1 24 | 1.76× | -1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
